ZHONG JI LS (00767) announced that on April 13, 2026, its wholly-owned subsidiary, Shenzhen Zhong Ji Health Science Co., Ltd., entered into a joint venture agreement with Guangdong Liang Jing Jing Technology Co., Ltd. The agreement concerns the establishment of a joint venture company in the People's Republic of China. Upon formation, Zhong Ji Health will hold a 51% stake in the joint venture, while Liang Jing Jing will hold 49%. The primary focus of the joint venture will be to provide global AI-driven vision health and longevity products and services, aiming to construct the world's first AI-powered vision health ecosystem platform. The initial registered capital of the joint venture is set at RMB 1 million, which will be contributed by Zhong Ji Health and Liang Jing Jing in proportion to their respective equity shares. These funds will primarily serve as working capital for the joint venture's operations. The Group intends to finance its capital commitments using internal resources upon completion of the registration process with the Chinese Administration for Industry and Commerce. The establishment of the joint venture aligns with the Group's strategic development plans for its longevity science business and is expected to benefit the Group's future business growth. The joint venture is committed to creating the world's first AI-powered vision health ecosystem, focusing on the research, development, production, and comprehensive marketing of AI technology-based eye care products. Leveraging foundational products such as the world's only AI vision correction glasses, IPS exosome eye drops, and lutein series, the company aims to build a full-chain AI vision health ecosystem, positioning itself as a benchmark brand in the global technology-driven eye care sector. The Board believes that the joint venture agreement will further enhance the Group's footprint in the longevity science field, open up new revenue streams in this area, and is expected to provide the Group with more stable and sustainable long-term income growth.